- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05845372
Associação do uso profilático de medicamentos para úlcera de estresse e desfechos clínicos em pacientes com trombectomia aguda da circulação anterior
Associação do uso profilático de medicamentos para úlcera de estresse e resultados clínicos em pacientes com trombectomia aguda da circulação anterior: um estudo de coorte prospectivo, multicêntrico e observacional
Ischemic stroke accounts for a relatively high proportion of strokes. In recent years, intravenous thrombolysis and endovascular therapy have significantly improved the revascularization rate in patients with large vessel occlusive cerebral infarction, but 20-50% of patients still experience ineffective revascularization. Therefore, postoperative monitoring and treatment of patients with large vessel occlusions is crucial for early recognition, management and prevention of complications. Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, and a previously proven incidence of stress ulcer bleeding after ischemic stroke. Stress ulcer bleeding after ischemic stroke has been shown to be closely associated with unfavorable outcomes, such as mortality. Current national and international guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for the prevention of stress ulcers, but rather should be considered in the context of the patient's risk factors for stress ulcers and discontinued after the patient initiates enteral nutrition. However, there is no evidence-based medical evidence to support the risk-benefit relationship of stress ulcer drug prophylaxis in patients with mechanical thrombectomy for acute anterior circulation large vessel occlusion.
Visão geral do estudo
Status
Condições
Descrição detalhada
Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, of which only 0.5%-1% require blood transfusion or result in hypotension. Stress ulcer bleeding after ischemic stroke has been shown to be associated with poor outcomes, such as mortality, and basilar artery occlusion and middle cerebral artery cerebral infarction are independent risk factors for stress ulcer bleeding after acute ischemic stroke. Guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for stress ulcer prevention.
However, stress ulcer prophylaxis is initiated in most patients admitted to the neurological intensive care unit after mechanical embolization of acute anterior circulation large vessel occlusion. With advances such as diagnosis and early initiation of enteral nutrition, the rate of stress ulcer bleeding in patients with mechanical embolization of acute anterior circulation large vessel occlusion is significantly reduced. The relationship between the risk and benefit of SUP in patients undergoing mechanical embolization for acute anterior circulation large vessel occlusion is not yet supported by evidence-based medical evidence. Therefore, the purpose of this study was to investigate the correlation between pharmacological stress ulcer prophylaxis and clinical outcomes in patients undergoing mechanical thrombectomy for acute anterior circulation large vessel occlusion.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Suyue Pan, M.D., Ph.D.
- Número de telefone: 13556184981
- E-mail: pansuyue@smu.edu.cn
Locais de estudo
-
-
Fujian
-
Fuzhou, Fujian, China
- Recrutamento
- Fujian Medical University Union Hospital
-
Contato:
- Shenggen Chen, M.D.
- Número de telefone: 13459480275
-
-
Guangdong
-
Dongguan, Guangdong, China
- Recrutamento
- Dongguan People's Hospital
-
Contato:
- Zhu Shi, M.D.
- Número de telefone: 13669825459
-
Dongguan, Guangdong, China
- Recrutamento
- Dongguan donghua hospital
-
Contato:
- Lingyu Sun
- Número de telefone: 13829203368
-
Guangzhou, Guangdong, China
- Recrutamento
- Nanfang Hospital of Southern Medical University
-
Contato:
- Suyue Pan
- Número de telefone: 13556184981
-
Guangzhou, Guangdong, China
- Recrutamento
- Guangdong Provincial Hospital of Traditional Chinese Medicine
-
Contato:
- Lixin Wang, M.D.
- Número de telefone: 13922793886
-
Guangzhou, Guangdong, China
- Recrutamento
- Huadu District People's Hospital of Guangzhou
-
Contato:
- Guangning Li, M.D.
- Número de telefone: 13926239656
-
Guangzhou, Guangdong, China
- Recrutamento
- The Fourth Affiliated Hospital of Guangzhou Medical University
-
Contato:
- Wangchi Luo, M.D.
- Número de telefone: 13710895142
-
Heyuan, Guangdong, China
- Recrutamento
- Heyuan people's Hospital
-
Contato:
- Minzhen Zhu
- Número de telefone: 15007622318
-
Huizhou, Guangdong, China
- Recrutamento
- Huizhou Municipal Central Hospital
-
Contato:
- Lizhi Wang, M.D.
- Número de telefone: 13802872076
-
-
Hainan
-
Haikou, Hainan, China
- Recrutamento
- Hainan Provincial People's Hospital
-
Contato:
- Fan Zhang, M.D.
- Número de telefone: 17389897580
-
Haikou, Hainan, China
- Recrutamento
- Haikou People's Hospital
-
Contato:
- Guoshuai Yang, M.D.
- Número de telefone: 13876006248
-
Haikou, Hainan, China
- Recrutamento
- Hainan Traditional Chinese Medicine Hospital
-
Contato:
- Yong Gu, M.D.
- Número de telefone: 15521280288
-
-
Hunan
-
Changsha, Hunan, China
- Recrutamento
- The First Hospital of Changsha
-
Contato:
- Xu Peng, M.D。
- Número de telefone: 15802507292
-
Hengyang, Hunan, China
- Recrutamento
- The Second Hospital University of South China
-
Contato:
- Yanhong Hu, M.D.
- Número de telefone: 13265004191
-
Yueyang, Hunan, China
- Recrutamento
- Yueyang People's Hospital
-
Contato:
- Yuan Zhou, M.D.
- Número de telefone: 15107309796
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, China
- Recrutamento
- Sinopharm North Hospital
-
Contato:
- Lifei Xing, M.D
- Número de telefone: 15354919958
-
Hohhot, Inner Mongolia, China
- Recrutamento
- The Affiliated Hospital of Inner Mongolia Medical University
-
Contato:
- Lihua Sun, M.D.
- Número de telefone: 18686292585
-
-
Jiangxi
-
Ganzhou, Jiangxi, China
- Recrutamento
- Ganzhou City People's Hospital
-
Contato:
- Zhaohui Lai
- Número de telefone: 13879729792
-
-
Zhejiang
-
Wenzhou, Zhejiang, China
- Recrutamento
- Second Affiliated Hospital of Wenzhou Medical University
-
Contato:
- Saijun Zhou, M.D.
- Número de telefone: 13857746659
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients who are treated with mechanical thrombectomy with acute anterior circulation large vessel occlusion. ≥18 years of age, within 24 hours of onset. Expected survival >3 months. NIHSS score ≥ 6 at onset of illness.
Descrição
Inclusion Criteria:
- Age ≥18 years.
- Within 24 hours of onset. Meet the criteria for diagnosis of acute ischemic stroke in the "China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018".
- Meet the indications for mechanical thrombectomy in the "Chinese Guidelines for Early Endovascular Interventions in Acute Ischemic Stroke 2022".
- Treated with mechanical thrombectomy.
- NIHSS score ≥ 6 at onset of illness.
- Sign an informed notice.
Exclusion Criteria:
Allergy to drug ingredients. Women who are pregnant or breastfeeding. Life expectancy of less than 3 months due to other non-ischemic stroke diseases such as malignancy, severe liver or renal failure.
Have participated in other interventional clinical studies (affecting the outcome of this cohort study).
Participants who were judged by the investigator to be unsuitable for participation in this study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Stress Ulcer Prophylaxis
Subjects are on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission. |
|
Control Group
Subjects are not on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
90-day mortality after onset
Prazo: 90-day after onset
|
Proportion of enrolled patients who died 90 days after onset of disease. |
90-day after onset
|
|
Incidence of stroke-associated pneumonia
Prazo: within 7-day of onset
|
Incidence of non-mechanically ventilated stroke patients with new pneumonia within 7-day of onset |
within 7-day of onset
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of clinically significant bleeding
Prazo: within 7-day of onset
|
One of the following 4 symptoms occurs within 24 hours of bleeding from a stress ulcer (in the absence of other causes):1. A decrease of ≥ 20 mmHg in any one of systolic, diastolic and mean arterial pressure. 2.Initiation of blood pressure boosters or 20% increase in medication dose.3. Decreased hemoglobin ≥ 2 g/d((1.24 mmol/l). 4.Infusion of erythrocytes ≥ 2 U. |
within 7-day of onset
|
|
Incidence of stress ulcer bleeding
Prazo: 7-day after onset
|
Coffee-like residue/black stool/blood in stool within 7-day after onset and more than 2 consecutive positive fecal/gastric fluid occult blood |
7-day after onset
|
|
Incidence of unfavorable functional prognosis at 90 days after onset
Prazo: 90-day after onset
|
Incidence of unfavorable functional prognosis at 90 days after onset |
90-day after onset
|
|
90-day mRS score change
Prazo: 90-day after onset
|
Modified Rankin Scale score change within 90 days after onset in patients who were eligible for inclusion criteria |
90-day after onset
|
|
Incidence of early neurological deterioration
Prazo: within 72 hours after onset
|
Increased score of National Institutes of Health Stroke Scale within 72h after onset ≥ 4 |
within 72 hours after onset
|
|
1-year post-onset mortality
Prazo: 1 year after onset
|
Mortality at 1 year after onset in patients who were eligible for inclusion criteria |
1 year after onset
|
|
Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset
Prazo: 1 year after onset
|
Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset in patients who were eligible for inclusion criteria |
1 year after onset
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Suyue Pan, Department of Neurology, Nanfang Hospital,Southern Medical University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NFEC-2023-040
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .